There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT – Research Report), Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) and Centessa Pharmaceuticals (CNTA – Research Report) with bullish sentiments.
Corcept Therapeutics (CORT)
In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Corcept Therapeutics, with a price target of $38.00. The company’s shares closed last Monday at $22.30, close to its 52-week low of $20.84.
According to TipRanks.com, Nash is a 3-star analyst with an average return of
Corcept Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $37.00.
See the top stocks recommended by analysts >>
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, with a price target of $83.00. The company’s shares closed last Monday at $36.02.
According to TipRanks.com, Seigerman is a 3-star analyst with an average return of
Currently, the analyst consensus on Structure Therapeutics, Inc. Sponsored ADR is a Strong Buy with an average price target of $83.00, which is a 127.5% upside from current levels. In a report issued on April 9, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $65.00 price target.
Centessa Pharmaceuticals (CNTA)
In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Centessa Pharmaceuticals, with a price target of $15.00. The company’s shares closed last Monday at $10.00.
According to TipRanks.com, Biliouris is a 1-star analyst with an average return of
Currently, the analyst consensus on Centessa Pharmaceuticals is a Strong Buy with an average price target of $13.00, a 19.3% upside from current levels. In a report issued on April 10, Leerink Partners also reiterated a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CORT:
- Biotech Alert: Searches spiking for these stocks today
- Corcept Therapeutics completes enrollment in Phase 2 DAZALS trial
- Upcoming Deadline to Share in Corcept Therapeutics Incorporated (CORT) Class Action Settlement
- Corcept Therapeutics completes enrollment in Phase 3 ROSELLA trial
- Corcept Therapeutics completes enrollment in Phase 3 GRADIENT trial
